Retrospective evaluation of the dose equivalence of Botox ® and Dysport ® in the management of blepharospasm and hemifacial spasm: A novel paradigm for a never ending story

Neurological Sciences

Volumn 33, Issue 2, 2012, Pages 261-269

  Bentivoglio, Anna Rita ^a   Ialongo, Tàmara ^a   Bove, Francesco ^a   De Nigris, Francesca ^a   Fasano, Alfonso ^a,b  

^a CATHOLIC UNIVERSITY   (Italy)

^b IRCCS ISTITUTO CENTRO SAN GIOVANNI DI DIO FATEBENEFRATELLI   (Italy)

Author keywords

Blepharospasm; Botox; Botulinum toxin; Dose equivalence ratio; Dysport; Hemifacial spasm

Indexed keywords

BOTULINUM TOXIN A;

ADULT; AGED; ARTICLE; BIOEQUIVALENCE; BLEPHAROSPASM; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HEMIFACIAL SPASM; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; RELIABILITY; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; BLEPHAROSPASM; BOTULINUM TOXINS, TYPE A; FEMALE; HEMIFACIAL SPASM; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84863982462     PISSN: 15901874     EISSN: 15903478     Source Type: Journal    
DOI: 10.1007/s10072-011-0672-7     Document Type: Article

References (27)

1. Dressler D, Hallet M (2006) Immunological aspects of Botox, Dysport and Myobloc/Neurobloc. Eur J Neurol 13(Suppl 1):S11-S15
2. Sampaio C, Costa J, Ferreira JJ (2004) Clinical comparability of marketed formulationsof botulinum toxin. Mov Disord 19(Suppl. 8):S129-S136 (Pubitemid 38967522)
3. Jost WH, Kohl A (2001) Botulinum toxin: evidence-based medicine criteria in blepharospasm and hemifacial spasm. J Neurol 248(Suppl 1):21-24
4. Albanese A, Barnes MP, Bhatia KP, Fernandez E, Filippini G, Gasser T, Krauss JK, Newton A, Rektor I, Savoiardo M, Valls-Solè J (2006) A systematic review on the diagnosis and treatment of primary (idiopathic) dystonia and dystonia plus syndromes. Report by an EFNS/MDS-ES Task Force. Eur J Neurol 13:433-444 (Pubitemid 43823355)
5. Digre K, Corbett JJ (1988) Hemifacial spasm: differential diagnosis, mechanism, and treatment. Adv Neurol 49:151-176
6. Jankovic J, Orman J (1984) Blepharospasm: demographic and clinical survey of 250 patients. Ann Ophthalmol 16:371-376 (Pubitemid 14144384)
7. Burke RE, Fahn S, Marsden CD, Bressman SB, Moskowitz C, Friedman J (1985) Validity and reliability of a rating scale for the primary torsion dystonias. Neurology 35:73-77 (Pubitemid 15193623)
8. Aoki KR, Ranoux D, Wissel J (2006) Using translational medicine to understand clinical differences between botulinum toxin formulations. Eur J Neurol 13(Suppl 4):10-19 (Pubitemid 44748279)
9. Wohlfarth K, Goschel H, Frevert J, Dengler R, Bigalke H (1997) Botulinum A toxins: units versus units. Naunyn Schmiedebergs Arch Pharmacol 355:335-340 (Pubitemid 27117590)
10. Marchetti A, Magar R, Findley L, Larsen JP, Pirtosek Z, Růzicka E, Jech R, Slawek J, Ahmed F (2005) Retrospective evaluation of the dose of Dysport and BOTOX in the management of cervical dystonia and blepharospasm: the REAL DOSE study. Mov Disord 20:937-944 (Pubitemid 41419507)
11. Sampaio C, Ferreira JJ, Simões F, Rosas MJ, Magalhães M, Correia AP, Bastos-Lima A, Martins R, Castro-Caldas A (1997) DYSBOT: a single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A-Dysport and Botox-assuming a ratio of 4:1. Mov Disord 12:1013-1018 (Pubitemid 27496782)
12. Nussgens Z, Roggenkamper P (1997) Comparison of two botulinum-toxin preparations in the treatment of essential blepharospasm. Graefes Arch Clin Exp Ophthalmol 235:197-199 (Pubitemid 27326086)
13. Odergren T, Hjaltason H, Kaakkola S, Solders G, Hanko J, Fehling C, Marttila RJ, Lundh H, Gedin S, Westergren I, Richardson A, Dott C, Cohen H (1998) A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport and Botox in the treatment of cervical dystonia. J Neurol Neurosurg Psychiatry 64:6-12 (Pubitemid 28156530)
14. Ranoux D, Gury C, Fondarai J, Mas JL, Zuber M (2002) Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia. J Neurol Neurosurg Psychiatry 72:459-462
15. Dressler D (2002) Dysport produces intrinsically more swallowing problems than Botox: unexpected results from a conversion factor study in cervical dystonia. J Neurol Neurosurg Psychiatry 73:604 (Pubitemid 35246828)
16. Wohlfarth K, Kampe K, Bigalke H (2004) Pharmacokinetic properties of different formulations of botulinum neurotoxin type A. Mov Disord 19 Suppl 8:S65-S67 (Pubitemid 38967514)
17. Mclellan K, Das RE, Ekong TA, Sesardic D (1996) Therapeutic botulinum type A toxin: factors affecting potency. Toxicon 34:975-985 (Pubitemid 26320008)
18. Binari K (2005) Safety, effectiveness, and duration of effect of BOTOX after switching from Dysport for blepharospasm, cervical dystonia, and hemifacial spasm. Curr Med Res Opin 21:433-438
19. Brashear A (2008) Clinical comparisons of botulinum neurotoxin formulations. Neurol 14:289-298
20. Wenzel R, Jones D, Borrego JA (2007) Comparing two botulinum toxin type A formulations using manufacturers product. J Clin Pharm Ther 32:387-402 (Pubitemid 47063164)
21. Marion MH, Sheehy M, Sangla S, Soulayrol S (1995) Dose standardisation of botulinum toxin. J Neurol Neurosurg Psychiatry 59:102-103
22. Durif D (1995) Clinical bioequivalence of the current commercial preparations of botulinum toxin. Eur J Neurol 2:17-18
23. Van den Bergh PY, Lison DF (1998) Dose standardization of botulinum toxin. Adv Neurol 78:231-235
24. Annese V, Bassotti G, Coccia G, D'Onofrio V, Gatto G, Repici A, Andriulli A (1999) Comparison of two different formulations of botulinum toxin A for the treatment of oesophageal achalasia The Gismad Achalasia Study Group. Aliment Pharmacol Ther 13:1347-1350 (Pubitemid 29462311)
25. Simonetta Moreau M, Cauhepe C, Magues JP, Senard JM (2003) A double-blind, randomized, comparative study of Dysport versus Botox in primary palmar hyperhidrosis. Br J Dermatol 149:1041-1045 (Pubitemid 37541992)
26. Brisinda G, Albanese A, Cadeddu F, Bentivoglio AR, Mabisombi A, Marniga G, Maria G (2004) Botulinum neurotoxin to treat chronic anal fissure: results of a randomized "Botox vs. Dysport" controlled trial. Aliment Pharmacol Ther 19:695-701 (Pubitemid 38445431)
27. Karsai S, Adrian R, Hammes S, Thimm J, Raulin C (2007) A randomized double-blind study of the effect of Botox and Dysport/Reloxin on forehead wrinkles and electromyographic activity. Arch Dermatol 143:1447-1449 (Pubitemid 350146281)